Pathways of methamphetamine toxicity: Effects of autophagy and SOD alteration in the spinal cord

Annals of the New York Academy of Sciences

Volumn 1139, Issue , 2008, Pages 177-185

  Ferrucci, Michela ^a   Pasquali, Livia ^a   Paparelli, Antonio ^a   Ruggieri, Stefano ^b   Fornai, Francesco ^a,b  

^a UNIVERSITY OF PISA   (Italy)

^b IRCCS NEUROMED   (Italy)

Author keywords

Autophagy; G93A mice; Methamphetamine; Motor neurons; Neurodegeneration; Spinal cord

Indexed keywords

COPPER ZINC SUPEROXIDE DISMUTASE; METHAMPHETAMINE; SUPEROXIDE DISMUTASE; UBIQUITIN;

ADOLESCENT; AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; AUTOPHAGY; CELL VACUOLE; CONFERENCE PAPER; CONTROLLED STUDY; DEGENERATIVE DISEASE; DRUG ABUSE; GENE MUTATION; MOTONEURON; MOUSE; NEUROTOXICITY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; SPINAL CORD; TRANSGENIC MOUSE;

MUS; MUS MUSCULUS;

EID: 53549131004     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1432.013     Document Type: Conference Paper

References (79)

1. Seiden, L.S., M.W. Fischman & C.R. Schuster. 1976. Long-term methamphetamine induced changes in brain catecholamines in tolerant rhesus monkeys. Drug Alcohol Depend. 1 : 215 219.
2. Hotchkiss, A. & J.W. Gibb. 1980. Blockade of methamphetamine-induced depression of tyrosine hydroxylase by GABA transaminase inhibitors. Eur. J. Pharmacol. 66 : 201 205.
3. Ricaurte, G.A., R.W. Guillery, L.S. Seiden, et al. 1982. Dopamine nerve terminal degeneration produced by high doses of methylamphetamine in the rat brain. Brain Res. 235 : 93 103.
4. Seiden, L.S. 1985. Methamphetamine: toxicity to dopaminergic neurons. NIDA Res. Monogr. 62 : 100 116.
5. Wilson, J.M., K.S. Kalasinsky, A.I. Levey, et al. 1996. Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat. Med. 2 : 699 703.
6. Fornai, F., P. Lenzi, M. Gesi, et al. 2004. Methamphetamine produces neuronal inclusions in the nigrostriatal system and in PC12 cells. J. Neurochem. 88 : 114 123.
7. Fornai, F., P. Lenzi, M. Ferrucci, et al. 2005. Occurrence of neuronal inclusions combined with increased nigral expression of alpha-synuclein within dopaminergic neurons following treatment with amphetamine derivatives in mice. Brain Res. Bull. 65 : 405 413.
8. Gluck, M.R., L.Y. Moy, E. Jayatilleke, et al. 2001. Parallel increases in lipid and protein oxidative markers in several mouse brain regions after methamphetamine treatment. J. Neurochem. 79 : 152 160.
9. Imam, S.Z., J. el-Yazal, G.D. Newport, et al. 2001. Methamphetamine- induced dopaminergic neurotoxicity: role of peroxynitrite and neuroprotective role of antioxidants and peroxynitrite decomposition catalysts. Ann. N. Y. Acad. Sci. 939 : 366 380.
10. Lazzeri, G., P. Lenzi, C.L. Busceti, et al. 2007. Mechanisms involved in the formation of dopamine-induced intracellular bodies within striatal neurons. J. Neurochem. 101 : 1414 1427.
11. Cubells, J.F., S. Rayport, G. Rajendran, et al. 1994. Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress. J. Neurosci. 14 : 2260 2271.
12. Larsen, K.E., E.A. Fon, T.G. Hastings, et al. 2002. Methamphetamine- induced degeneration of dopaminergic neurons involves autophagy and upregulation of dopamine synthesis. J. Neurosci. 22 : 8951 8960.
13. Quan, L., T. Ishikawa, T. Michiue, et al. 2005. Ubiquitin-immunoreactive structures in the midbrain of methamphetamine abusers. Leg. Med. (Tokyo) 7 : 144 150.
14. Gesi, M., P. Soldani, F.S. Giorgi, et al. 2000. The role of the locus coeruleus in the development of Parkinson's disease. Neurosci. Biobehav. Rev. 24 : 655 668.
15. Fornai, F., A.B. di Poggio, A. Pellegrini, et al. 2007. Noradrenaline in Parkinson's disease: from disease progression to current therapeutics. Curr. Med. Chem. 14 : 2330 2334.
16. Rommelfanger, K.S. & D. Weinshenker. 2007. Norepinephrine: the redheaded stepchild of Parkinson's disease. Biochem. Pharmacol. 74 : 177 190.
17. Guilarte, T.R. 2001. Is methamphetamine abuse a risk factor in parkinsonism? Neurotoxicology. 22 : 725 731.
18. Betarbet, R., T.B. Sherer & J.T. Greenamyre. 2002. Animal models of Parkinson's disease. Bioessays 24 : 308 318.
19. Cadet, J.L., P. Sheng, S. Ali, et al. 1994. Attenuation of methamphetamine-induced neurotoxicity in copper/zinc superoxide dismutase transgenic mice. J. Neurochem. 62 : 380 383.
20. Cadet, J.L., S.F. Ali, R.B. Rothman, et al. 1995. Neurotoxicity, drugs and abuse, and the CuZn-superoxide dismutase transgenic mice. Mol. Neurobiol. 11 : 155 163.
21. Imam, S.Z., G.D. Newport, Y. Itzhak, et al. 2001. Peroxynitrite plays a role in methamphetamine-induced dopaminergic neurotoxicity: evidence from mice lacking neuronal nitric oxide synthase gene or overexpressing copper-zinc superoxide dismutase. J. Neurochem. 76 : 745 749.
22. Rosen, D.R., T. Siddique, D. Patterson, et al. 1993. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362 : 59 62.
23. Cleveland, D.W. & J.D. Rothstein. 2001. From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat. Rev. Neurosci. 2 : 806 819.
24. Rowland, L.P. 1998. Diagnosis of amyotrophic lateral sclerosis. J. Neurol. Sci. 160 (Suppl. 1 S6 S24.
25. Martin, L.J. 2007. Transgenic mice with human mutant genes causing Parkinson's disease and amyotrophic lateral sclerosis provide common insight into mechanisms of motor neuron selective vulnerability to degeneration. Rev. Neurosci. 18 : 115 136.
26. Ravits, J., P. Paul & C. Jorg. 2007. Focality of upper and lower motor neuron degeneration at the clinical onset of ALS. Neurology 68 : 1571 1575.
27. Gurney, M.E., H. Pu, A.Y. Chiu, et al. 1994. Motor neuron degeneration in mice that express a human Cu/Zn superoxide dismutase mutation. Science. 264 : 1772 1775.
28. Martin, L.J., Z. Liu, K. Chen, et al. 2007. Motor neuron degeneration in amyotrophic lateral sclerosis mutant superoxide dismutase-1 transgenic mice: mechanisms of mitochondriopathy and cell death. J. Comp. Neurol. 500 : 20 46.
29. Dal Canto, M.C. & M.E. Gurney. 1994. Development of central nervous system pathology in a murine transgenic model of human amyotrophic lateral sclerosis. Am. J. Pathol. 145 : 1271 1279.
30. Kong, J. & Z. Xu. 1998. Massive mitochondrial degeneration in motor neurons triggers the onset of amyotrophic lateral sclerosis in mice expressing a mutant SOD1. J. Neurosci. 18 : 3241 3250.
31. Bruijn, L.I., M.K. Houseweart, S. Kato, et al. 1998. Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science 281 : 1851 1854.
32. Seilhean, D., J. Takahashi, K.H. El Hachimi, et al. 2004. Amyotrophic lateral sclerosis with neuronal intranuclear protein inclusions. Acta Neuropathol. 108 : 81 87.
33. Ota, S., K. Tsuchiya & H. Akiyama. 2005. "Forme fruste" of amyotrophic lateral sclerosis with dementia: a report of five autopsy cases without dementia and with ubiquitinated intraneuranal inclusions. Neuropathology 25 : 326 335.
34. Yokota, O., K. Tsuchiya, T. Oda, et al. 2006. Amyotrophic lateral sclerosis with dementia: an autopsy case showing many Bunina bodies, tau-positive neuronal and astrocytic plaque-like pathologies, and pallido-nigral degeneration. Acta Neuropathol. 112 : 633 645.
35. Portera-Cailliau, C., C. Russ, R.H. Jr. Brown, et al. 2007. A familial form of pallidoluysionigral degeneration and amyotrophic lateral sclerosis with divergent clinical presentations. J. Neuropathol. Exp. Neurol. 66 : 650 659.
36. Shintaku, M., K. Oyanagi & D. Kaneda. 2007. Amyotrophic lateral sclerosis with dementia showing clinical parkinsonism and severe degeneration of the substantia nigra: report of an autopsy case. Neuropathology 27 : 295 299.
37. Wagner, G.C., G.A. Ricaurte, L.S. Seiden, et al. 1980. Long-lasting depletions of striatal dopamine and loss of dopamine uptake sites following repeated administration of methamphetamine. Brain Res. 181 : 151 160.
38. Itzhak, J. & C. Achat-Mendes. 2004. Methamphetamine and MDMA (ecstasy) neurotoxicity: "of mice and men". IUBMB Life. 56 : 249 255.
39. Riddle, E.L., A.E. Fleckenstein & G.R. Hanson. 2006. Mechanisms of methamphetamine-induced dopaminergic neurotoxicity. AAPS J. 8 : 413 418.
40. Ricaurte, G.A. & U.D. McCann. 2005. Recognition and management of complications of new recreational drug use. Lancet 365 : 2137 2145.
41. Deng, H.-X., A. Hentati, J.A. Tainer, et al. 1993. Amyotrophic lateral sclerosis and structural defects in Cu, Zn superoxide dismutase. Science 261 : 1047 1051.
42. Rubinsztein, D.C. 2006. The roles of intracellular protein-degradation pathways in neurodegeneration. Nature 443 : 780 786.
43. Samantaray, S., V.H. Knaryan, M.K. Guyton, et al. 2007. The parkinsonian neurotoxin rotenone activates calpain and caspase-3 leading to motoneuron degeneration in spinal cord of Lewis rats. Neuroscience 146 : 741 755.
44. Ray, S.K., G.G. Wilford, S.F. Ali, et al. 2000. Calpain up-regulation in spinal cord of mice with 1-methyl-4 phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinson's disease. Ann. N.Y. Acad. Sci. 914 : 275 283.
45. Chera, B., K.E. Schaecher, A. Rocchini, et al. 2002. Calpain up-regulation and neuron death in spinal cord of MPTP-induced parkinsonism in mice. Ann. N.Y. Acad. Sci. 965 : 274 280.
46. Chera, B., K.E. Schaecher, A. Rocchini, et al. 2004. Immunofluorescent labelling of increased calpain expression and neuronal death in the spinal cord of 1-methyl-4 phenyl-1,2,3,6-tetrahydropyridine-treated mice. Brain Res. 1006 : 150 156.
47. Masliah, E., E. Rockenstein, I. Weinbergs, et al. 2000. Dopaminergic loss and inclusions body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 287 : 1265 1269.
48. Van Der Putten, H., K.-H. Wiederhold, A. Probst, et al. 2000. Neuropathology in mice expressing human alpha-synuclein. J. Neurosci. 20 : 6021 6029.
49. Martin, L.J., Y. Pan, A.C. Price, et al. 2006. Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. J. Neurosci. 26 : 41 50.
50. Kabuta T., Y. Suzuki & K. Wada. 2006. Degradation of amyotrophic lateral sclerosis-linked mutant Cu,Zn-superoxide dismutase proteins by macroautophagy and the proteasome. J. Biol. Chem. 281 : 30524 30533.
51. Mariño, G. & C. López-Otín. 2004. Autophagy: molecular mechanisms, physiological functions and relevance in human pathology. Cell. Mol. Life Sci. 61 : 1439 1454.
52. Yang, Y., A. Hentati, H.X. Deng, et al. 2001. The gene encoding alsin, a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis. Nat. Genet. 29 : 160 165.
53. Hadano, S., C.K. Hand, H. Osuga, et al. 2001. A gene encoding a putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis 2. Nat. Genet. 29 : 166 173.
54. Nishimura, A.L., M. Mitne-Neto, H.C. Silva, et al. 2004. A mutation in the vesicle-trafficking protein VAPB causes late-onset spinal muscular atrophy and amyotrophic lateral sclerosis. Am. J. Hum. Genet. 75 : 822 831.
55. Puls, I., C. Jonnakuty, B.H. LaMonte, et al. 2003. Mutant dynactin in motor neuron disease. Nat. Genet. 33 : 455 456.
56. Chance, P.F., B.A. Rabin, S.G. Ryan, et al. 1998. Linkage of the gene for an autosomal dominant form of juvenile amyotrophic lateral sclerosis to chromosome 9q34. Am. J. Hum. Genet. 62 : 633 640.
57. Chen, Y.Z., C.L. Bennett, H.M. Huynh, et al. 2004. DNA/RNA helicase gene mutations in a form of juvenile amyotrophic lateral sclerosis (ALS4). Am. J. Hum. Genet. 74 : 1128 1135.
58. Greenway, M.J., P.M. Andersen, C. Russ, et al. 2006. ANG mutations segregate with familial and "sporadic" amyotrophic lateral sclerosis. Nat. Genet. 38 : 411 413.
59. Otomo, A., S. Hadano, T. Okada, et al. 2003. ALS2, a novel guanine nucleotide exchange factor for the small GTPase Rab5, is implicated in endosomal dynamics. Hum. Mol. Genet. 12 : 1671 1687.
60. Topp, J.D., N.W. Gray, R.D. Gerard, et al. 2004. Alsin is a Rab5 and Rac1 guanine nucleotide exchange factor. J. Biol. Chem. 279 : 24612 24623.
61. Schroer, T.A. 2004. Dynactin. Annu. Rev. Cell. Dev. Biol. 20 : 759 779.
62. Gruzman, A., W.L. Wood, E. Alpert, et al. 2007. Common molecular signature in SOD1 for both sporadic and familial amyotrophic lateral sclerosis. PNAS 104 : 12524 12529.
63. Comi, G.P., A. Bordoni, S. Salani, et al. 1998. Cytochrome c oxidase subunit I microdeletion in a patient with motor neuron disease. Ann. Neurol. 43 : 110 116.
64. Borthwick, G.M., R.W. Taylor, T.J. Walls, et al. 2006. Motor neuron disease in a patient with a mitochondrial tRNAIle mutation. Ann. Neurol. 59 : 570 574.
65. Ravikumar, B., A. Acevedo-Arozena, S. Imarisio, et al. 2005. Dynein mutations impair autophagic clearance of aggregate-prone proteins. Nat. Genet. 37 : 771 776.
66. Levy, J.R., C.J. Sumner, J.P. Caviston, et al. 2006. A motor neuron disease-associated mutation in p150Glued perturbs dynactin function and induces protein aggregation. J. Cell. Biol. 172 : 733 745.
67. Kim, I., S. Rodriguez-Enriquez & J.J. Lemasters. 2007. Selective degradation of mitochondria by mitophagy. Arc. Biochem. Biophys. 462 : 245 253.
68. Ravikumar, B., R. Duden & D.C. Rubinsztein. 2002. Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy. Hum. Mol. Genet. 11 : 1107 1117.
69. Landles, C. & G.P. Bates. 2004. Huntingtin and the molecular pathogenesis of Huntington's disease (Fourth in molecular medicine review series). EMBO Rep. 5 : 958 963.
70. Kegel, K.B., M. Kim, E. Sapp, et al. 2000. Huntingtin expression stimulates endosomal-lysosomal activity, endosome tubulation, and autophagy. J. Neurosci. 20 : 7268 7278.
71. Pandey, U.B., Z. Nie, Y. Batlevi, et al. 2007. HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS. Nature 447 : 859 863.
72. Kiffin, R., C. Christian, E. Knecht, et al. 2004. Activation of chaperone-mediated autophagy during oxidative stress. Mol. Biol. Cell. 15 : 4829 4834.
73. Sarkar, S. R.A. Floto, Z. Berger, et al. 2005. Lithium induces autophagy by inhibiting inositol monophosphatase. J. Cell. Biol. 170 : 1101 1111.
74. Raught, B., A.C. Gingras & N. Sonenberg. 2001. The target of rapamycin (TOR) proteins. Proc. Natl. Acad. Sci. 98 : 7037 7044.
75. Pasquali, L., G. Lazzeri, C. Isidoro, et al. 2008. Role of autophagy during methamphetamine neurotoxicity. Drug Addiction: Research Frontiers. This volume.
76. Sarkar, S., G. Krishna, S. Imarisio, et al. 2007. A rational mechanism for combination treatment of Huntington's disease using lithium and rapamycin. Hum. Mol Genet. E-pub ahead of print.
77. Yamamoto B.K. & M.G. Bankson. 2005. Amphetamine neurotoxicity: cause and consequence of oxidative stress. Crit. Rev. Neurobiol. 17 : 87 117.
78. Martin, L.J. 2006. Mitochondriopathy in Parkinson disease and amyotrophic lateral sclerosis. J. Neuropathol. Exp. Neurol. 65 : 1103 1110.
79. Struewing, I.T., C.D. Barnett, T. Tang, et al. 2007. Lithium increases PGC-1alpha expression and mitochondrial biogenesis in primary bovine aortic endothelial cells. FEBS J. 274 : 2749 2765.